Title: Inflammasome-independent IL-1β mediates autoinflammatory disease in Pstpip2-deficient mice.

Authors: Cassel, Suzanne L; Janczy, John R; Bing, Xinyu; Wilson, Shruti P; Olivier, Alicia K; Otero, Jesse E; Iwakura, Yoichiro; Shayakhmetov, Dmitry M; Bassuk, Alexander G; Abu-Amer, Yousef; Brogden, Kim A; Burns, Trudy L; Sutterwala, Fayyaz S; Ferguson, Polly J

Published In Proc Natl Acad Sci U S A, (2014 Jan 21)

Abstract: Chronic recurrent multifocal osteomyelitis (CRMO) is a human autoinflammatory disorder that primarily affects bone. Missense mutation (L98P) of proline-serine-threonine phosphatase-interacting protein 2 (Pstpip2) in mice leads to a disease that is phenotypically similar to CRMO called chronic multifocal osteomyelitis (cmo). Here we show that deficiency of IL-1RI in cmo mice resulted in a significant reduction in the time to onset of disease as well as the degree of bone pathology. Additionally, the proinflammatory cytokine IL-1β, but not IL-1α, played a critical role in the pathology observed in cmo mice. In contrast, disease in cmo mice was found to be independent of the nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3 (NLRP3) inflammasome as well as caspase-1. Neutrophils, but not bone marrow-derived macrophages, from cmo mice secreted increased IL-1β in response to ATP, silica, and Pseudomonas aeruginosa compared with neutrophils from WT mice. This aberrant neutrophil response was sensitive to inhibition by serine protease inhibitors. These results demonstrate an inflammasome-independent role for IL-1β in disease progression of cmo and implicate neutrophils and neutrophil serine proteases in disease pathogenesis. These data provide a rationale for directly targeting IL-1RI or IL-1β as a therapeutic strategy in CRMO.

PubMed ID: 24395802

MeSH Terms: No MeSH terms associated with this publication